Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-136317

Published: 2020

Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138612

Published: 2020

Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137655

Published: 2020

Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1751.

https://doi.org/10.1182/blood-2019-127102

Published: 2019

Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 1759.

https://doi.org/10.1182/blood-2019-131099

Published: 2019

Journal Articles

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Jennifer Woyach, MD, Ying Huang, MS, MA, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Arletta Lozanski, Tzyy-Jye Doong, James S. Blachly, MD, Gerard Lozanski, MD, Dan Jones, MD PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 504.

https://doi.org/10.1182/blood-2019-127674

Published: 2019

Journal Articles

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Caner Saygin, MD, Arletta Lozanski, Tzyy-Jye Doong, Shelley Orwick, BS, Deedra Nicolet, MS, Jadwiga Labanowska, Nyla A. Heerema, PhD, Rosa Lapalombella, PhD, Gregory K. Behbehani, MD PhD, John C. Byrd, MD, Gerard Lozanski, MD, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 186.

https://doi.org/10.1182/blood-2019-125285

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

Eileen Hu, BS, Hatice Gulcin Ozer, PhD, Arletta Lozanski, Tzyy-Jye Doong, Chi-Ling Chiang, PhD, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, James S. Blachly, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 3377.

https://doi.org/10.1182/blood-2019-126070

Published: 2019

Journal Articles

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Dan Jones, MD PhD, Huolin Tu, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Xiaokang Pan, PhD, Susan Long, Brianna Sisson, Sean Caruthers, Peng Ru, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Lynne V. Abruzzo, MD PhD, Weiqiang Zhao, MD PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2018-99-116293

Published: 2018

Journal Articles

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Blood (2018) 132 (Supplement 1): 6.

https://doi.org/10.1182/blood-2018-99-116653

Published: 2018

Journal Articles

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Mirela Anghelina, Narendranath Epperla, MD MS, Kerry A. Rogers, MD, Ling Guo, MD, Qiuhong Zhao, MS, James S. Blachly, MD, David M. Lucas, PhD, Christopher C. Oakes, Gerard Lozanski, MD, Michael R. Grever, MD, Leslie A. Andritsos, MD

Blood (2018) 132 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2018-99-120043

Published: 2018

Journal Articles

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment

Narendranath Epperla, MDMS, Mirela Anghelina, Qiuhong Zhao, MS, Akwasi Agyeman, James S. Blachly, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Christopher C. Oakes, Michael R. Grever, MD, Leslie Andritsos, MD

Blood (2018) 132 (Supplement 1): 2305.

https://doi.org/10.1182/blood-2018-99-119951

Published: 2018

Journal Articles

Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, Guillaume Cartron, Michael Hallek, Barbara Eichhorst, Mark F. Kozloff, Thomas Giever, Gerard Lozanski, MD, Yanwen Jiang, Huang Huang, Daniela Soriano Pignataro, William Schary, Kathryn Humphrey, Mehrdad Mobasher, MD MPH, Gilles Salles, MD PhD

Blood (2018) 132 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2018-99-118362

Published: 2018

Journal Articles

Enhanced Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients

Bethany L Mundy-Bosse, PhD, Nathan Denlinger, MS, DO, Susan Huang, MD, Li Chen, Hsiaoyin Mao, David Kline, Eric McLaughlin, Youssef Youssef, Karen Young, Gerard Lozanski, MD, Aharon G. Freud, MD PhD, Pierluigi Porcu, MD, Basem M. William, MD, Michael A. Caligiuri, MD, Anjali Mishra, PhD

Blood (2017) 130 (Supplement 1): 2753.

https://doi.org/10.1182/blood.V130.Suppl_1.2753.2753

Published: 2017

Journal Articles

Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance

Michael Keeney, ART,FIMLS(D), Brent L. Wood, MD PhD, Benjamin Hedley, PhD, Joseph A. DiGiuseppe, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Elisabeth Paietta, PhD, Gerard Lozanski, MD, Adam C. Seegmiller, MD PhD, Bruce W Greig, BS/ MT(ASCP)CCy, Aaron C. Shaver, MD PhD, Lata Mukundan, PhD, Howard R. Higley, PhD, Caroline C Sigman, PhD, Gary Kelloff, MD, John Milburn Jessup, MD, Michael J Borowitz, MD PhD

Blood (2016) 128 (22): 2907.

https://doi.org/10.1182/blood.V128.22.2907.2907

Published: 2016

Journal Articles

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh T. Awan, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 4386.

https://doi.org/10.1182/blood.V128.22.4386.4386

Published: 2016

Journal Articles

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Jeffrey A. Jones, MD MPH, Amy J. Johnson, PhD, Farrukh T. Awan, Quihong Zhao, MAS, Natarajan Muthusamy, DVM, PhD, Kami J. Maddocks, MD, Leslie A. Andritsos, MD, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, Gerard Lozanski, MD, Nyla A. Heerema, PhD, Cathy Brookfield, BSN, Amy S Ruppert, MAS, John C. Byrd, MD

Blood (2016) 128 (22): 4388.

https://doi.org/10.1182/blood.V128.22.4388.4388

Published: 2016

Journal Articles

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Daniel R Richardson, MD, Qiuhong Zhao, MS, Rhonda Kitzler, MS, Patrick Elder, MS, Gerard Lozanski, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Sam Penza, MD, Sumithra Vasu, MBBS, Steven M Devine, MD

Blood (2016) 128 (22): 4598.

https://doi.org/10.1182/blood.V128.22.4598.4598

Published: 2016

Journal Articles

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, MD, Guillaume Cartron, MD PhD, Michael Hallek, Barbara F. Eichhorst, MD, Mark Kozloff, MD, Thomas A. Giever, Gerard Lozanski, MD, Elizabeth A. Punnoose, PhD, Jue Wang, James Hilger, PhD, Mehrdad Mobasher, MD, Gilles Salles, MD PhD

Blood (2016) 128 (22): 4393.

https://doi.org/10.1182/blood.V128.22.4393.4393

Published: 2016

NARROW

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment

Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)

Enhanced Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients

Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only